The place of the L-asparaginase in the treatment of acute leukemias.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000818:Animals; D001215:Asparaginase / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D004342:Drug Hypersensitivity; D005260:Female; D006084:Graft Rejection / Q000187:drug effects; D006087:Graft vs Host Reaction / Q000187:drug effects; D006410:Hematopoiesis; D006801:Humans; D007165:Immunosuppression Therapy; D007223:Infant; D007938:Leukemia / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008111:Liver Function Tests; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D011087:Polycythemia Vera / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use; D012756:Sheep / Q000276:immunology; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D001215:Asparaginase; D011241:Prednisone